Details of the Drug
General Information of Drug (ID: DMOFG4M)
| Drug Name |
2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
17775-01-8; 2,3,4,5-Tetrahydrobenzo[f][1,4]oxazepine; 2,3,4,5-tetrahydro-1,4-benzoxazepine; 2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine; CHEMBL118420; 1,4-Benzoxazepine, 2,3,4,5-tetrahydro-; 2.3.4.5-tetrahydro-benzo[f][1,4]oxazepine; 1,4-Benzoxazepine, 2,3,4,5-tetrahydro-, hydrochloride; AC1Q1IB5; AC1Q1IB6; SCHEMBL400964; CTK4D6590; DTXSID90619367; HDVHFHONOKCUHQ-UHFFFAOYSA-N; MolPort-001-792-633; KS-00000I8M; ALBB-011885; CT-115; BDBM50052890; ZINC11802711; ANW-65610; STK897763; AKOS005173482; MCULE-4987146186; CS-W007152; BS-12101
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 149.19 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 1 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


